- ►onlinejacc.org D Cardinale, MT Sandri, A Martinoni, A Tricca … - Journal of the American College of Cardiology, 2000 - Elsevier In the cTnI− group, left ventricular ejection fraction (LVEF) progressively
decreased after HDC, reaching a maximal reduction after three months; however,
myocardial depression was transient and no longer detectable at later ... Cited by 123 - Related articles - BL Direct - All 18 versions
LJ Steinherz, PG Steinherz, C Tan - Pediatric Blood & Cancer - interscience.wiley.com The clinical course of late symptomatic anthracycline cardiomyopathy, and
resultant changes of cardiac function, were described in 15 patients. They
represented a subset of 300 patients who had cardiac evaluations to ... Cited by 117 - Related articles - BL Direct - All 3 versions
- ►onlinejacc.org J Feenstra, DE Grobbee, WJ Remme, BHC … - Journal of the American College of Cardiology, 1999 - Elsevier Heart failure is a clinical syndrome that is predominantly caused by
cardiovascular disorders such as coronary heart disease and hypertension.
However, several classes of drugs may induce heart failure in patients ... Cited by 66 - Related articles - BL Direct - All 8 versions
J Wojtacki, E Lewicka-Nowak… - Medical science monitor: international medical journal … - ncbi.nlm.nih.gov Anthracycline antibiotics are widely used antineoplastic agents and their
efficacy for the treatment of various haemopoietic or solid tumours has been
well established in clinical practice. Cardiotoxicity is one of the most ... Cited by 59 - Related articles - BL Direct - All 4 versions
- ►bmj.com [PDF] FA Bu'Lock, MG Mott, A Oakhill, RP Martin - British Medical Journal, 1996 - adc.bmj.com Abstract The number of survivors of childhood cancer affected by anthracycline
cardio- myopathy is steadily increasing, despite efforts to limit cardiotoxicity
by dose restriction. Cardiac function was evalu- ated prospectively in 125 ... Cited by 49 - Related articles - BL Direct - All 10 versions
- ►nih.gov [PDF] DA Dodd, JB Atkinson, RD Olson, S Buck, BJ … - Journal of Clinical Investigation, 1993 - pubmedcentral.nih.gov Doxorubicin is a highly effective cancer chemotherapeutic agent that produces a
dose-dependent cardiomyopathy that lim- its its clinical usefulness. Clinical
and animal studies ofmorpho- logical changes during the early stages of ... Cited by 49 - Related articles - BL Direct - All 7 versions
RE Shaddy, SL Olsen, MR Bristow, DO Taylor, … - American Heart Journal, 1995 - Elsevier 4. SM Heilbrun, P Shah, MR Bristow, HA Valantine, R Ginsburg and MB Fowler,
Increased β-receptor density and improved hemodynamic response to catecholamine
stimulation during long-term metoprolol therapy in heart failure from ... Cited by 45 - Related articles - BL Direct - All 3 versions
D Jain - Journal of Nuclear Cardiology, 2000 - Springer Doxorubicin (Adriamycin), an anthracycline glyco- side antibiotic, is a potent
chemotherapeutic agent useful in the treatment of a wide variety of tumors. 1-4
A number of anthracycline derivatives such as doxorubicin, daunorubicin, ... Cited by 37 - Related articles - BL Direct - All 2 versions
I Mitani, D Jain, TM Joska, B Burtness, BL … - Journal of Nuclear Cardiology, 2003 - Springer Patients with a normal baseline LVEF ( > 50%) and a 10% or greater point fall in
LVEF to a final value of less than 50% during doxorubicin therapy were
considered “at risk” for CHF (n 41). Over 679 426 days of follow-up, 7 ... Cited by 33 - Related articles - BL Direct - All 4 versions
JS Moreb, DJ Oblon - CA A Cancer Journal for Clinicians - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 31 - Related articles - BL Direct - All 4 versions
